New Reimbursement May Level Playing Field for Biosimilars


The Bipartisan Budget Act of 2018 (BBA 2018) directly affects Medicare Part D drugs, but its impact could expand beyond. Precision for Value’s Joanne Mai and Andrew Cournoyer cover how this change in the Medicare coverage gap program represents a small step toward encouraging biosimilar development, containing drug prices, and improving patient access.

To read the full article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.